Dynavax Technologies | DVAX - Przychody Ze Sprzedaży



Obroty Zmiana Data
AbbVie USD 16.62B 840M 2025-12
Adma Biologics USD 139.16M 4.94M 2025-12
Agenus USD 34.2M 3.97M 2025-12
Amgen USD 9.9B 340M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
Biogen USD 2.28B 250M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Gilead Sciences USD 7.93B 130M 2025-12
Glaxosmithkline GBP 11.46B 59.16M 2025-12
Merck USD 16.4B 880M 2025-12
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 24.12M 635K 2024-09
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Novartis USD 13.86B 50M 2025-12
Pfizer USD 17.58B 880M 2025-12
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
TG Therapeutics USD 192.57M 30.87M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12